People · Operator

William Fuller

Named in public records as an officer, director or promoter · active 2017–2023 · Biotechnology, Healthtech

2
Companies
7
Filings
$16.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
S4 Medical Corp.BiotechnologySeries A$12.0M$49.5M2017
Okapi Medical, LLCHealthtechSeed$4.8M$5.9M2021
Operator network

William Fuller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Roy Tanaka · 6 companies · 1 sharedRoy TanakaV. Kadir Kadhiresan · 5 companies · 1 sharedV. Kadir Kadhires…Bill Baumel · 3 companies · 1 sharedBill BaumelHirak Parikh · 3 companies · 1 sharedHirak ParikhAnila Lingamneni · 1 companies · 1 sharedAnila LingamneniEmile Daod · 1 companies · 1 sharedEmile DaodEmile Daoud · 1 companies · 1 sharedEmile DaoudRoy Kadir Tanaka · 1 companies · 1 sharedRoy Kadir TanakaDavid Kay · 6 companies · 1 sharedDavid KayCherie Friedman · 1 companies · 1 sharedCherie FriedmanDarren Obrigkeit · 1 companies · 1 sharedDarren ObrigkeitGabriel Szabo · 1 companies · 1 sharedGabriel SzaboRich Mazzola · 1 companies · 1 sharedRich MazzolaRussell Donda · 1 companies · 1 sharedRussell DondaS4 Medical Corp. · $12.0M raisedS4 Medical Corp.Okapi Medical, LLC · $4.8M raisedOkapi Medical, LLCWilliam FullerWF
William Fuller Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside William Fuller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David Kay16
Roy Tanaka16
V. Kadir Kadhiresan15
Bill Baumel13
Hirak Parikh13
Darren Obrigkeit11
Rich Mazzola11
Anila Lingamneni11
Emile Daod11
Roy Kadir Tanaka11
Emile Daoud11
Russell Donda11
Gabriel Szabo11
Cherie Friedman11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.